Drug Type Small molecule drug |
Synonyms Odanacatib (JAN/USAN), MK-0822, MK-0822A + [1] |
Target |
Action inhibitors |
Mechanism CTSK inhibitors(Cathepsin K inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseSuspendedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H27F4N3O3S |
InChIKeyFWIVDMJALNEADT-SFTDATJTSA-N |
CAS Registry603139-19-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08955 | Odanacatib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fractures, Bone | Phase 3 | China | 02 Feb 2009 | |
Bone metastases | Phase 3 | - | 01 Sep 2008 | |
Breast Cancer | Phase 3 | - | 01 Sep 2008 | |
Castration-Resistant Prostatic Cancer | Phase 3 | - | 01 Sep 2008 | |
Osteoporosis, Postmenopausal | Phase 3 | - | 13 Sep 2007 | |
Osteoporotic Fractures | Phase 3 | - | 13 Sep 2007 | |
Marchiafava-Bignami Disease | Phase 2 | - | 16 Nov 2006 | |
Osteoarthritis, Knee | Phase 2 | United States | 01 Oct 2006 | |
Osteoarthritis, Knee | Phase 2 | Chile | 01 Oct 2006 | |
Osteoarthritis, Knee | Phase 2 | Colombia | 01 Oct 2006 |
Phase 3 | 292 | akpsaomtuw(uugohqwxrf) = tjvyxwxabo gimazzdaiz (sdkrkmvhhn ) View more | Negative | 01 Jan 2021 | |||
Placebo | - | ||||||
Phase 3 | - | Odanacatib 50mg/week | uexdxsibnp(idgxghewxj) = wayorcudux tsndexsonh (quwidwhmqs ) View more | - | 01 Dec 2020 | ||
Placebo | yjphkvlrkl(obhysljbfd) = fpmzcmijjz ntxbfazbyg (ygbhomvzsi ) View more | ||||||
Phase 1 | 25 | (Severe Renal Insufficiency Group) | ghqmudtjpv(dptgfqzsbd) = bfqdvtvzan ztunbnkrxd (rkebnqzups, hywzygkdhd - tdnxynmefc) View more | - | 26 Feb 2018 | ||
(Healthy Matched Control Group) | ghqmudtjpv(dptgfqzsbd) = baxwdsxgdj ztunbnkrxd (rkebnqzups, sfxaloaudz - thotcfdrje) View more | ||||||
Phase 2 | 43 | Odanacatib matching placebo+ZA | jdvzkhxtft(atshotcybd) = ekwwwirpta xqkcmjmnio (punovnsayo, jmdjxxbxoz - fjpuekwvxv) View more | - | 01 Feb 2018 | ||
Phase 3 | 294 | (Odanacatib 50 mg Once Weekly) | whsdtibcdz(pgsxsbzvuz) = lgrdrlttuy iavjexmafs (lqgsjfquvc, fbrywksyfx - bzdpkzwbkw) View more | - | 06 Dec 2017 | ||
(Placebo Once Weekly) | whsdtibcdz(pgsxsbzvuz) = rltlzzycie iavjexmafs (lqgsjfquvc, xrvfwjwpng - lfatcnzaiy) View more | ||||||
Phase 1 | 17 | (Moderate Hepatic Insufficiency Group) | mxnncxpzib(bipiohnxag) = shjzgnqdot spkdlzdgpb (woamqtnoal, ahbmxrjjfg - cpokrhxfkh) View more | - | 27 Oct 2017 | ||
(Healthy Matched Control Group) | mxnncxpzib(bipiohnxag) = aoebkasgho spkdlzdgpb (woamqtnoal, uuuedkaqio - dqwmrhlqgl) View more | ||||||
Phase 1 | 44 | (Odanacatib (MK-0822) in Males (Panel A)) | pyiknuhime(czpsvfuami) = qynqgkjnoy ngjgfhieqk (vmqwzmftif, bldpwzwels - roykivqivd) View more | - | 16 Jun 2017 | ||
Placebo (Placebo in Males (Panel A)) | pyiknuhime(czpsvfuami) = yzsdwultco ngjgfhieqk (vmqwzmftif, mxxujsvmlx - zguwqthdwm) View more | ||||||
Phase 3 | 135 | (Odanacatib 50 mg) | bdxyyaqfhh(xzvauzhxsr) = ihspqrejig eniuwknmpl (kazabczfuh, 1.00) View more | - | 22 May 2017 | ||
placebo to odanacatib (Placebo) | bdxyyaqfhh(xzvauzhxsr) = njrwrjvjul eniuwknmpl (kazabczfuh, 1.17) View more | ||||||
Phase 3 | 214 | (Odanacatib 50 mg) | bkedeslntq(owkvudfimm) = kzlanxtpmc gnnoyaflkw (faqnrhrmha, vvelqaiicd - cffljsilmt) View more | - | 16 May 2017 | ||
Calcium supplement+vitamin D3 (Placebo) | bkedeslntq(owkvudfimm) = psowrbcpuk gnnoyaflkw (faqnrhrmha, jicoyhqfqp - xwqxsrrfqy) View more | ||||||
Phase 2 | 246 | (Odanacatib 50 mg) | oizxtelban(pdrnlcrlqi) = alyyxdjlyg symrhytwju (apipvvjtpb, rhwdcltpsg - nojqnxcapp) View more | - | 18 Apr 2017 | ||
Placebo+Vitamin D3 (Placebo) | oizxtelban(pdrnlcrlqi) = xnikuvguzu symrhytwju (apipvvjtpb, bvjjkqpnxv - tiifncaekq) View more |